Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 5/2021

01-10-2021 | Lung Cancer | Author Correction

Author Correction to: Advances in anti-BRAF therapies for lung cancer

Authors: Giandomenico Roviello, Alberto D’Angelo, Marianna Sirico, Matteo Pittacolo, Felipe Umpierre Conter, Navid Sobhani

Published in: Investigational New Drugs | Issue 5/2021

Login to get access

Excerpt

Author Correction to: Investigational New Drugs …
Metadata
Title
Author Correction to: Advances in anti-BRAF therapies for lung cancer
Authors
Giandomenico Roviello
Alberto D’Angelo
Marianna Sirico
Matteo Pittacolo
Felipe Umpierre Conter
Navid Sobhani
Publication date
01-10-2021
Publisher
Springer US
Published in
Investigational New Drugs / Issue 5/2021
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-021-01092-8

Other articles of this Issue 5/2021

Investigational New Drugs 5/2021 Go to the issue

PRECLINICAL STUDIES

FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment

PRECLINICAL STUDIES

Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancer

SHORT REPORT

Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancer

PHASE II STUDIES

Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations

Letters to the Editor

Comment on “Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma”

SHORT REPORT

Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits